What's new

Human medicines European public assessment report (EPAR): Avamys, fluticasone furoate, Date of authorisation: 11/01/2008, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025 0

Human medicines European public assessment report (EPAR): Avamys, fluticasone fu...

Human medicines European public assessment report (EPAR): Cimzia, certolizumab pegol, Date of authorisation: 01/10/2009, Revision: 36, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025 0

Human medicines European public assessment report (EPAR): Cimzia, certolizumab p...

Human medicines European public assessment report (EPAR): Iclusig, ponatinib, Date of authorisation: 01/07/2013, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025 0

Human medicines European public assessment report (EPAR): Iclusig, ponatinib, Da...

Human medicines European public assessment report (EPAR): Flucelvax Tetra, influenza vaccine (surface antigen, inactivated, prepared in cell cultures), Date of authorisation: 12/12/2018, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025 0

Human medicines European public assessment report (EPAR): Flucelvax Tetra, influ...

Artificial intelligence

Artificial intelligence

Feb 18, 2025 0

Artificial intelligence

Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, Date of authorisation: 20/02/2023, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025 0

Human medicines European public assessment report (EPAR): Imjudo, tremelimumab, ...

Human medicines European public assessment report (EPAR): Spexotras, trametinib, Date of authorisation: 05/01/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025 0

Human medicines European public assessment report (EPAR): Spexotras, trametinib,...

Human medicines European public assessment report (EPAR): Vyndaqel, tafamidis, Date of authorisation: 16/11/2011, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025 0

Human medicines European public assessment report (EPAR): Vyndaqel, tafamidis, D...

Human medicines European public assessment report (EPAR): GoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.), budesonide,formoterol fumarate dihydrate, Date of authorisation: 03/04/2020, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025 0

Human medicines European public assessment report (EPAR): GoResp Digihaler (prev...

Checklist for the submission of Type IA and Type IB (wi...

Feb 18, 2025 0

Checklist for the submission of Type IA and Type IB (without linguistic review) ...

Type-IB variations: questions and answers

Type-IB variations: questions and answers

Feb 18, 2025 0

Type-IB variations: questions and answers

Worksharing: questions and answers

Worksharing: questions and answers

Feb 18, 2025 0

Worksharing: questions and answers

Changing the labelling and package leaflet (Article 61(3) notifications)

Changing the labelling and package leaflet (Article 61(...

Feb 18, 2025 0

Changing the labelling and package leaflet (Article 61(3) notifications)

Type-II variations: questions and answers

Type-II variations: questions and answers

Feb 18, 2025 0

Type-II variations: questions and answers

Transfer of marketing authorisation: questions and answers

Transfer of marketing authorisation: questions and answers

Feb 18, 2025 0

Transfer of marketing authorisation: questions and answers

European medicines agencies network strategy (EMANS) to 2028 webinar, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 13 February 2025, 13:00 (CET) to 13 February 2025, 17:00 (CET)

European medicines agencies network strategy (EMANS) to...

Feb 18, 2025 0

European medicines agencies network strategy (EMANS) to 2028 webinar, Online, Eu...

European Medicines Agency post-authorisation procedural...

Feb 18, 2025 0

European Medicines Agency post-authorisation procedural advice for users of the ...

European Medicines Agency post-authorisation procedural...

Feb 18, 2025 0

European Medicines Agency post-authorisation procedural advice for users of the ...

Agenda of the CAT meeting 19-21 February 2025

Feb 18, 2025 0

Agenda of the CAT meeting 19-21 February 2025

Quick guide: How to search, view and download a Clinica...

Feb 18, 2025 0

Quick guide: How to search, view and download a Clinical Trial and a Clinical Tr...

Quick guide - Introduction: CTIS for SMEs and Academia ...

Feb 18, 2025 0

Quick guide - Introduction: CTIS for SMEs and Academia - CTIS Training Programme...

FAQs: Introduction to the Clinical Trials Regulation (E...

Feb 18, 2025 0

FAQs: Introduction to the Clinical Trials Regulation (EU) No 536/2014 - CTIS Tra...

Referral: Finasteride- and dutasteride-containing medicinal products, finasteride,dutasteride Article 31 referrals Under evaluation, 18/02/2025

Referral: Finasteride- and dutasteride-containing medic...

Feb 18, 2025 0

Referral: Finasteride- and dutasteride-containing medicinal products, finasterid...

Human medicines European public assessment report (EPAR): Onureg, azacitidine, Date of authorisation: 17/06/2021, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025 0

Human medicines European public assessment report (EPAR): Onureg, azacitidine, D...

9
10
11
12
13

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.